Mechanisms of resistance to camptothecins

A. Saleem, T. K. Edwards, Z. Rasheed, E. H. Rubin

Research output: Contribution to journalArticle

Abstract

Camptothecins are broad-spectrum anticancer drugs that specifically target DNA topoisomerase I. Although the availability of camptothecins has had a significant impact on cancer therapeutics, de novo or acquired clinical resistance to camptothecins is common. Studies of camptothecin resistance using yeast and mammalian cell culture models suggest three general mechanisms of resistance: (1) reduced cellular accumulation of camptothecins, (2) alteration in the structure or location of topoisomerase I, and (3) alterations in the cellular response to camptothecin-DNA-ternary complex formation. The relevance of these mechanisms to clinical drug resistance is not yet known, but evaluation of these models in clinical specimens should enhance the use of camptothecins both as single agents and in combination with other anticancer drugs.

Original languageEnglish (US)
Pages (from-to)46-55
Number of pages10
JournalAnnals of the New York Academy of Sciences
Volume922
StatePublished - 2000
Externally publishedYes

Fingerprint

Camptothecin
Type I DNA Topoisomerase
Pharmaceutical Preparations
Cell culture
Drug Resistance
Yeast
Cell Culture Techniques
Yeasts
Availability
Alteration
Drugs
DNA

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Saleem, A., Edwards, T. K., Rasheed, Z., & Rubin, E. H. (2000). Mechanisms of resistance to camptothecins. Annals of the New York Academy of Sciences, 922, 46-55.

Mechanisms of resistance to camptothecins. / Saleem, A.; Edwards, T. K.; Rasheed, Z.; Rubin, E. H.

In: Annals of the New York Academy of Sciences, Vol. 922, 2000, p. 46-55.

Research output: Contribution to journalArticle

Saleem, A, Edwards, TK, Rasheed, Z & Rubin, EH 2000, 'Mechanisms of resistance to camptothecins', Annals of the New York Academy of Sciences, vol. 922, pp. 46-55.
Saleem A, Edwards TK, Rasheed Z, Rubin EH. Mechanisms of resistance to camptothecins. Annals of the New York Academy of Sciences. 2000;922:46-55.
Saleem, A. ; Edwards, T. K. ; Rasheed, Z. ; Rubin, E. H. / Mechanisms of resistance to camptothecins. In: Annals of the New York Academy of Sciences. 2000 ; Vol. 922. pp. 46-55.
@article{34d14e5347ba432a8e61e571345b792b,
title = "Mechanisms of resistance to camptothecins",
abstract = "Camptothecins are broad-spectrum anticancer drugs that specifically target DNA topoisomerase I. Although the availability of camptothecins has had a significant impact on cancer therapeutics, de novo or acquired clinical resistance to camptothecins is common. Studies of camptothecin resistance using yeast and mammalian cell culture models suggest three general mechanisms of resistance: (1) reduced cellular accumulation of camptothecins, (2) alteration in the structure or location of topoisomerase I, and (3) alterations in the cellular response to camptothecin-DNA-ternary complex formation. The relevance of these mechanisms to clinical drug resistance is not yet known, but evaluation of these models in clinical specimens should enhance the use of camptothecins both as single agents and in combination with other anticancer drugs.",
author = "A. Saleem and Edwards, {T. K.} and Z. Rasheed and Rubin, {E. H.}",
year = "2000",
language = "English (US)",
volume = "922",
pages = "46--55",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Mechanisms of resistance to camptothecins

AU - Saleem, A.

AU - Edwards, T. K.

AU - Rasheed, Z.

AU - Rubin, E. H.

PY - 2000

Y1 - 2000

N2 - Camptothecins are broad-spectrum anticancer drugs that specifically target DNA topoisomerase I. Although the availability of camptothecins has had a significant impact on cancer therapeutics, de novo or acquired clinical resistance to camptothecins is common. Studies of camptothecin resistance using yeast and mammalian cell culture models suggest three general mechanisms of resistance: (1) reduced cellular accumulation of camptothecins, (2) alteration in the structure or location of topoisomerase I, and (3) alterations in the cellular response to camptothecin-DNA-ternary complex formation. The relevance of these mechanisms to clinical drug resistance is not yet known, but evaluation of these models in clinical specimens should enhance the use of camptothecins both as single agents and in combination with other anticancer drugs.

AB - Camptothecins are broad-spectrum anticancer drugs that specifically target DNA topoisomerase I. Although the availability of camptothecins has had a significant impact on cancer therapeutics, de novo or acquired clinical resistance to camptothecins is common. Studies of camptothecin resistance using yeast and mammalian cell culture models suggest three general mechanisms of resistance: (1) reduced cellular accumulation of camptothecins, (2) alteration in the structure or location of topoisomerase I, and (3) alterations in the cellular response to camptothecin-DNA-ternary complex formation. The relevance of these mechanisms to clinical drug resistance is not yet known, but evaluation of these models in clinical specimens should enhance the use of camptothecins both as single agents and in combination with other anticancer drugs.

UR - http://www.scopus.com/inward/record.url?scp=0034509635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034509635&partnerID=8YFLogxK

M3 - Article

C2 - 11193924

AN - SCOPUS:0034509635

VL - 922

SP - 46

EP - 55

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -